ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Arvinas Inc

Arvinas Inc (ARVN)

33.14
0.90
(2.79%)
Closed May 31 4:00PM
33.14
0.00
(0.00%)
After Hours: 4:00PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
33.14
Bid
31.88
Ask
34.00
Volume
1,002,064
32.35 Day's Range 33.62
13.57 52 Week Range 53.08
Market Cap
Previous Close
32.24
Open
32.57
Last Trade
20
@
34
Last Trade Time
Financial Volume
$ 33,056,593
VWAP
32.9885
Average Volume (3m)
699,068
Shares Outstanding
68,083,928
Dividend Yield
-
PE Ratio
-6.15
Earnings Per Share (EPS)
-5.39
Revenue
78.5M
Net Profit
-367.3M

About Arvinas Inc

Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-... Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. Its pipeline candidates include metastatic castration-resistant prostate cancer, metastatic ER-breast cancer, additional oncology indications, tauopathies, and other neurodegenerative diseases. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Arvinas Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ARVN. The last closing price for Arvinas was $32.24. Over the last year, Arvinas shares have traded in a share price range of $ 13.57 to $ 53.08.

Arvinas currently has 68,083,928 shares outstanding. The market capitalization of Arvinas is $2.26 billion. Arvinas has a price to earnings ratio (PE ratio) of -6.15.

ARVN Latest News

Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress

NEW HAVEN, Conn., May 23, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two abstracts, including one for ARV-766 in prostate cancer and one for TACTIVE-K, a Phase...

Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)

– After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile of vepdegestrant in...

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress

NEW HAVEN, Conn., May 09, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two posters, including updated clinical trial data, for vepdegestrant will be presented at...

Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update

– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-2.17-6.1455678278135.3136.197431.552974134.0922909CS
4-0.66-1.9526627218933.837.3831.2467821033.50962414CS
12-15.55-31.936742657648.6949.7630.9169906836.98821635CS
268.8836.603462489724.2653.0821.6780142838.61187021CS
5211.351.739926739921.8453.0813.5763258232.60290349CS
156-39.66-54.47802197872.8108.46513.5751272646.57017882CS
26011.754.570895522421.44108.46513.5750018646.71056042CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NVOSNovo Integrated Sciences Inc
$ 1.05
(132.82%)
310.28M
BNAIBrand Engagement Network Inc
$ 5.4799
(112.40%)
67.99M
PRTGPortage Biotech Inc
$ 0.51
(98.44%)
4.26M
PLTNUPlutoniam Acquisition Corporation
$ 12.06
(81.63%)
1.81k
PEGRUProject Energy Reimagined Acquisition Corporation
$ 11.43
(36.89%)
1.19k
WBUYWeBuy Global Ltd
$ 0.241
(-61.75%)
22.54M
SMFLSmart for Life Inc
$ 3.40
(-43.05%)
2.77M
TOIIWOncology Institute Inc
$ 0.016
(-40.74%)
5.5k
SIFYSify Technologies Limited
$ 1.105
(-34.23%)
3.69M
LOTLotus Technology Inc
$ 9.78
(-25.00%)
832.27k
NVOSNovo Integrated Sciences Inc
$ 1.05
(132.82%)
310.28M
GWAVGreenwave Technology Solutions Inc
$ 0.0387
(-7.86%)
305.13M
FFIEFaraday Future Intelligent Electric Inc
$ 0.584899
(3.47%)
223.84M
SQQQProShares UltraPro Short QQQ
$ 10.02
(0.00%)
161.89M
CRKNCrown Electrokinetics Corporation
$ 0.0998
(-12.07%)
155.13M

ARVN Discussion

View Posts
Monksdream Monksdream 3 months ago
ARVN new 52=week high
👍️0
Monksdream Monksdream 4 months ago
ARVN new 52 week high
👍️0
Monksdream Monksdream 4 months ago
ARVN new 52 week high
👍️0
Monksdream Monksdream 5 months ago
ARVN new 52 week high
👍️0
crudeoil24 crudeoil24 3 years ago
ARVN up 138% > "Based on data to date, we believe ARV-471 is the most promising ER-targeting therapy in the clinic, showing early signs of efficacy, a favorable tolerability profile, and better ER degradation than that previously reported for fulvestrant, the current standard of care,” said Ron Peck, Ph.D., Chief Medical Officer at Arvinas. “It is exciting to see that ARV-110 continues to be active and well tolerated in what we believe is the most heavily pretreated patient population that has ever been studied with an AR-directed therapy. Our recently initiated ARDENT Phase 2 cohort expansion is specifically designed to investigate the potential of a precision medicine approach in molecularly defined, late-line patients with few available treatment options, while also fully characterizing the safety and activity of ARV-110 in earlier line patients irrespective of molecular profile, setting ARV-110 on a potential two-pronged registrational path.”
👍️0
biocqr biocqr 4 years ago
Advantages of PROTACs vs. inhibition...

message_id=152832655
👍️0
G-lupo G-lupo 5 years ago
Idk about that, I thought it had some resistance and kept going through, I think at this next convention their going to release some positive news. I’m so holy I didn’t sell at $30 which was ceiling I thought. Do have in a $35 limit sell thought if drops. Rebuy anything under $25
👍️0
boo boo boo boo 5 years ago
Starting to see a chink in the armor!
👍️0
G-lupo G-lupo 5 years ago
Possibly wall at 30.50
👍️0
G-lupo G-lupo 5 years ago
I feel people are going to start taking profits before $35 price target and give it a dip back.
Question is what is that dip price
👍️0
boo boo boo boo 5 years ago
The offering:

8-k
👍️0
boo boo boo boo 5 years ago
Benzinga 11/14/2019:

With a rating of Buy, Roth Capital initiated coverage on Arvinas Inc (NASDAQ:ARVN). The price target is set at $35.00 for Arvinas. In the third quarter, Arvinas showed an EPS of $0.21, compared to ($62.38) from the year-ago quarter. The current market cap for Arvinas is at $696.1 million. The stock has a 52-week-high of $28.96 and a 52-week-low of $10.19. Arvinas's stock last closed at $28.38 per share.

I might post a chart in about a week, well after everything plays out!
👍️0
boo boo boo boo 5 years ago
It doesn't have to be a PR:

#8
👍️0
G-lupo G-lupo 5 years ago
Thanks, I’m in it, thought $28 would be resistant and broke through looks may break $30
👍️0
boo boo boo boo 5 years ago
https://polsonnews.com/arvinas-inc-nasdaqarvn-receives-34-33-average-pt-from-brokerages/
👍️0
G-lupo G-lupo 5 years ago
When did they Do a price target announcement? I didn’t see that.
👍️0
boo boo boo boo 5 years ago
If I were in this one (I'm not), I'd be finding the exit on the price target announcement.
👍️0
G-lupo G-lupo 5 years ago
Arvn looking good, defintely see $26-27
👍️0
G-lupo G-lupo 5 years ago
What you mean IBD?
👍️0
boo boo boo boo 5 years ago
Not me. I look for the trade setup. Learned of this one from IBD and have been following...waiting. Missed the opportunity by 1 day. Would've, Should've, Could've...
👍️0
G-lupo G-lupo 5 years ago
I agree I own a decent amount, purchased from $22 down to $15.50. In for the long haul
👍️0
boo boo boo boo 5 years ago
Missing a trade and people who post a purchase at a specific price well after that price has passed.

The bottom of the prior range (July thru September) is resistance as far as I'm concerned and you have a couple important SMA's around there. And I agree that a break of $27 could lead to a higher price. Wouldn't be as confident if a press release occurred at the same time, but then again depends on what is said.
👍️0
G-lupo G-lupo 5 years ago
What are you talking about ?

Saw the rebound at $16, going to get probably Around $25-26, if gets there look for resistance to drop back. Like this stock and with more news if breaks $27 could see $60
👍️0
boo boo boo boo 5 years ago
Screwed this one up. More and better content on biotech values board. And no, I don't think this individual bought 'yesterday' and posted about it the day after. That's crap and not credible...POSER!
👍️0
boo boo boo boo 5 years ago
Fook R's!

EOM
👍️0
boo boo boo boo 5 years ago
Price is at the 100 Lower Linear Regression channel. Do we consolidate here and eventually move north. No position...yet!
👍️0
PennyStock Alert PennyStock Alert 5 years ago
ARVN
👍️0
G-lupo G-lupo 5 years ago
This stock very volatile, no rhyme or reason why it’s been up and down.
👍️0
morokoy morokoy 5 years ago
Las Vegas man 1st in world to use new experimental cancer drug, ARV 101.

https://www.reviewjournal.com/life/health/las-vegas-man-1st-in-world-to-use-new-experimental-cancer-drug-video-1654750/
👍️0